FOR IMMEDIATE RELEASE: August 4, 2017
Contact: Brad Bullen
(781) 647-3700 ext. 570
Nova Biomedical Launches New CE-Marked Critical Care
Stat Profile Prime Plus
New technologies improve and simplify testing
Waltham, MA – Nova Biomedical is pleased to announce that a new addition to the Stat Profile line of blood gas critical care analyzers, Stat Profile Prime Plus, has gained CE mark certification and is now available in all CE regulated countries. Prime Plus features maintenance-free sensor technology to provide 22 essential critical care tests including blood gases, electrolytes, metabolites, hematology, and co-oximetry. Prime Plus also features new and patented, non-lysing whole blood co-oximetry technology, along with automated quality control (QC), powerful data management, bidirectional connectivity, and extensive cybersecurity protection.
Prime Plus incorporates Nova’s innovative, maintenance-free sensor technology with individual MicroSensor cards, calibrator cartridges, and quality control cartridges. This design eliminates sensor and co-oximeter maintenance, improves analyzer uptime, and reduces testing costs for the compact and easy-to-use Prime Plus.
The MicroSensor Card™ provides 22 whole blood assays including co-oximetry and new critical care assays for urea, creatinine, and ionized magnesium. Prime Plus provides a complete co-oximetry panel without chemically or mechanically lysing the blood, which eliminates corrosive lysing reagents and mechanical complexity and improves instrument reliability and reduces costs.
Prime Plus delivers a comprehensive critical care panel in about one minute from 135 microliters of whole blood. Tests include pH, PCO2, PO2, SO2%, Na, K, Cl, iCa, iMg, TCO2, glucose, lactate, urea, creatinine, Hct, Hb, O2Hb, COHb, MetHb, HHb, HbF, and tBil. A unique safety sample port allows for easy docking and hands-free sampling, and the Clot Block™ sample flow path protects sensors from blood clot blockages and related downtime.
Prime Plus provides total quality monitoring with automated QC that verifies analyzer accuracy and precision on assayed liquid controls, and supplemental quality monitoring that electronically monitors and verifies correct performance of all analytical components for each analysis and calibration.
Prime Plus features a powerful data management system and bidirectional connectivity, remote analyzer review and control of connected Prime Plus analyzers, and the most comprehensive cybersecurity features to protect patient health information and prevent viruses.
“We at Nova Biomedical are extremely excited to launch the next addition to the Stat Profile Prime platform with Prime Plus,” said Brad Bullen, BS, RCP, sales product line manager at Nova. “Prime Plus introduces technology that expands critical care testing with unique assays and eliminates sensor and co-oximeter maintenance, all of which improves uptime and reduces costs. Prime Plus represents the latest in critical care testing technology and further demonstrates Nova’s leadership and history of innovation.”
About Nova Biomedical
Incorporated in 1976 and based in Waltham, MA, Nova Biomedical is a world leader in the development and manufacturing of state-of-the-art, whole blood, point-of-care and critical care analyzers, as well as providing the biotechnology industry with the most advanced instruments for cell culture monitoring. Nova is one of the fastest growing in vitro diagnostic companies in the world. Nova’s biosensor technology is incorporated in products ranging from handheld meters for glucose self- and point-of-care testing to critical care whole blood analyzers designed for rapid measurement of over 20 analytes. Nova’s biotechnology-specific BioProfile line has pioneered comprehensive cell culture testing, providing over 16 critical cell culture tests with 12 unique instrument offerings for broad range of cell culture applications. Nova employs over 1,200 people worldwide and has wholly owned subsidiaries located in Brazil, Canada, France, Germany, Great Britain, Italy, Japan, Spain, Switzerland, and Taiwan.